Hempyreum.org
Local Time
English (UK) Deutsch (DE) Français (FR) Español (ES) Italian (IT)
InMed Signs R&D Agreement with ATERA
Author: Bryan Mc Govern 10/07/2017 - 16:12:00

InMed Pharmaceuticals (CSE:; OTCQB:IMLFF) entered into a research and development collaboration with ATERA

As quoted in the press release: 

Under the terms of the agreement, ATERA will develop 3D human skin models of Epidermolysis Bullosa (‘EB’) to evaluate the in vitro drug efficacy of InMed’s lead compound, INM-750, a proprietary, topical cannabinoid product candidate targeted as a therapy in EB and other potential dermatological and wound-healing applications. ATERA will also investigate the beneficial effects of topically applied INM-750 at ultra-structural cellular and molecular levels on in vitro 3D reconstructed human full thickness (dermis-epidermis) skin models composed of both normal and EB-derived skin cells. 

“INM-750 has demonstrated significant potential in pre-clinical models to address symptomatic improvement of EB including accelerated wound healing and a reduction in pain, itch and inflammation.  This project with ATERA is designed to assess the potential of INM-750 to have an impact in disease reversal, further supporting our current data indicating an up-regulation in specific keratins in the skin”, stated Dr. Sazzad Hossain, CSO of InMed. “By utilizing full-thickness skin models derived from EB skin samples, we can better validate INM-750’s target effect and efficacy in vitro ahead of our upcoming clinical trial program.”

Click here to read the full press release.

The post InMed Signs R&D Agreement with ATERA appeared first on Investing News Network.

Original article from cannabisinvestingnews.com:InMed Signs R&D Agreement with ATERA



10/07/2017 - 16:12:00
info
Total pages / language:   22'347 / 13'841
In the archive :   46'559
Pages last 24 hours:   22
This Month Pages:   838
Views:   4'609'391
Views Archive:   9'626'343

©2017 - Hempyreum.org - News about Hemp and Cannabis [Beta] | All rights and ownership of the contents belong to their respective holders

Advertising